Effect of US Drug Enforcement Administration's Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing

JAMA Intern Med. 2016 Mar;176(3):399-402. doi: 10.1001/jamainternmed.2015.7799.

Authors

Christopher M Jones¹, Peter G Lurie², Douglas C Throckmorton²

Affiliations

¹ Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services, Washington, DC.
² Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland.

PMID: 26809459
DOI: 10.1001/jamainternmed.2015.7799

No abstract available

Publication types

Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Analgesics, Opioid* / therapeutic use
Drug Combinations*
Drug Prescriptions / standards*
Humans
Hydrocodone* / therapeutic use
Legislation, Drug*
Linear Models
Practice Patterns, Physicians' / statistics & numerical data
Practice Patterns, Physicians' / trends*
Prescription Drugs* / therapeutic use
Primary Health Care / statistics & numerical data
Primary Health Care / trends
United States

Substances

Analgesics, Opioid
Drug Combinations
Prescription Drugs
Hydrocodone